Filing identity and reporting period
Important mismatch: The supplied filing is a Form 10-Q for Rosewind Corporation, a development-stage sailing-school business—not Aytu BioPharma, Inc. It covers the quarter and nine months ended May 31, 2014, not 2013 Q3 as stated in the request metadata. The filing was signed July 10, 2014.
Financial results and liquidity
| Metric | Three months ended May 31, 2014 | Three months ended May 31, 2013 | Nine months ended May 31, 2014 | Nine months ended May 31, 2013 |
|---|---|---|---|---|
| Revenue | $1,000 | $1,750 | $1,000 | $1,750 |
| Operating expenses | $12,132 | $13,708 | $47,698 | $45,091 |
| Operating loss | $11,132 | $11,958 | $46,698 | $43,341 |
| Interest expense | $692 | $1,307 | $3,829 | $3,441 |
| Net loss | $11,824 | $13,265 | $50,527 | $46,782 |
| Net loss per share | $0.00 | $0.00 | $0.01 | $0.01 |
Gross margin is not provided. For the nine months, operating cash use was $29,609, compared with $32,470 in the prior-year period; financing provided $36,716, including $19,016 in related-party loan proceeds and $17,700 from stock sales. Cash increased by $7,107 to $8,969.
At May 31, 2014, total assets were $13,496, current liabilities were $49,539, and shareholders’ equity was a deficit of $36,043. The company reported a $39,977 working-capital deficit. Related-party loans payable were $28,526, with $17,202 of accrued related-party interest. The remaining loan bears 6% interest, is payable on demand, and is secured by the sailing vessel.
Changes, financing, and unusual items
- Nine-month revenue fell to $1,000 from $1,750, while net loss increased to $50,527 from $46,782. Management cited higher consulting and interest costs, partly offset by lower boat repair, maintenance, and management expenses.
- During the nine months, the company issued 118,000 shares for $17,700 cash, 100,000 shares valued at $15,000 for services, and 600,000 shares to convert $90,000 of related-party debt. It also issued 20,000 shares to settle a $3,000 subscription.
- Since inception, reported revenue was $6,250 and operating expenses were $596,230; accumulated development-stage losses were $618,731.
Outlook, risks, and contingencies
Management stated that cash was insufficient to sustain the business and planned to seek additional equity funding; there is no assurance funding will be available. The filing says substantial doubt exists about the company’s ability to continue as a going concern. No specific financial guidance or quantified forecast is provided.
- The sailing-school business had limited revenue and an unproven ability to attract paying students. The filing variously says two students had paid full tuition, three paying students had been located, and six students had been trained; these descriptions are not reconciled.
- Risks include vessel maintenance and safety, weather and voyage hazards, uncertain demand, dependence on one officer who also performs key operational roles, and possible dilution from future financing.
- The company said it had limited insurance and was seeking improved coverage. It also described uncertainty over possible foreign licensing requirements and California taxes, including a disputed Alameda County personal-property-tax assessment.
- Management reported disclosure controls were effective and no material changes in internal control during the quarter.
Key facts for investors to verify
- Confirm the filing is for Rosewind Corporation and the period ended May 31, 2014; it does not match the requested Aytu BioPharma 2013 Q3 filing.
- Reconcile the student counts and tuition descriptions, and the filing’s $1,000 nine-month revenue with its discussion of $6,250 cumulative revenue and the May 2014 voyage.
- Review the going-concern disclosure, cash needs, and the terms and status of related-party borrowing and any planned equity financing.
- Assess licensing, insurance, California tax, and vessel-related safety and operating exposures.
- Note a small reported net-loss inconsistency: the statements show $50,527 for the nine months, while MD&A states $50,528.